NCT03508869

Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Skin Laser & Surgery Specialists · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

To evaluate the safety and efficacy of Mirvaso® Gel and Dysport® for erythema and flushing of Rosacea.

Detailed description

To assess the improvement of facial erythema and flushing while using Mirvaso® and Dysport® treatments based on the clinician's and patient's assessments using a verified 5-point grading scale

Conditions

• Erythema and Flushing Associated With Rosacea

Interventions

Type	Name	Description
DRUG	Mirvaso® (brimonidine) topical gel, 0.33%	Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
DRUG	Dysport®	Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
DRUG	Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%	Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%

Timeline

• Start date: 2016-09-27
• Primary completion: 2017-09-20
• Completion: 2017-09-20
• First posted: 2018-04-26
• Last updated: 2023-04-18